Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 2, 2001, Pages 222-223

  Beasley, Richard ^a   Burgess, Carl ^a   Holt, Shaun ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Asthma; Benzalkonium chloride; Nebulizer solutions; Paradoxical bronchoconstriction

Indexed keywords

BENZALKONIUM CHLORIDE; BRONCHODILATING AGENT; EDETIC ACID; HISTAMINE; IPRATROPIUM BROMIDE; ORCIPRENALINE; SALBUTAMOL;

ASTHMA; BRONCHOSPASM; DRUG SAFETY; EDITORIAL; HUMAN; MAST CELL; NEBULIZER; PRIORITY JOURNAL;

EID: 0035113615     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.112941     Document Type: Article

References (14)

1. Benzalkonium chloride: Selective inhibitor of histamine release induced by compound 48/80 and other polyamines
2. Immunoglobulin E decapeptide-induced 5-hydroxytryptamine release from rat peritoneal mast cells
3. Preservatives in nebulizer solutions: Risks without benefit
4. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution
5. The contribution of histamine release to bronchoconstriction in asthma
6. The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma
7. Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride
8. A comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebulizer solution
9. The effect of benzalkonium chloride on the bronchodilator response to albuterol nebuliser solution
10. Possible associations of benzalkonium chloride in nebulizer solutions with respiratory arrest
11. Benzalkonium chloride and bronchoconstriction
12. Bronchoconstrictor additives in bronchodilator solutions
13. Pulmonary function response to EDTA, an additive in nebulized bronchodilators
14. Preservatives in nebulizer solutions: Risks without benefit - A further comment